-
Study aim
-
Comparison of the effects of dorzolamide eye drops versus placebo (artificial tears) on the prevention of macular thickening following phacoemulsification surgery in diabetic patients
-
Design
-
This study is designed as a clinical trial and includes 68 eyes from 68 diabetic patients undergoing phaco surgery.
-
Settings and conduct
-
Phacoemulsification surgery in all patients is performed using the same technique. Postoperative examinations are conducted at 1 day, 1 week, 4 weeks, and 12 weeks after surgery, while macular OCT imaging is performed at 1 week, 4 weeks, and 12 weeks postoperatively.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria: Patients with controlled diabetes who are candidates for phacoemulsification cataract surgery.
Exclusion Criteria: Complicated phacoemulsification surgery; history of glaucoma; uveitis; previous ocular surgery; intravitreal drug injection within the past 3 months; history of retinal photocoagulation laser treatment within the past 6 months; presence of proliferative diabetic retinopathy (PDR); macular edema (central macular thickness greater than 320 microns); any prior macular disease and media opacity affecting the quality of OCT macular imaging
-
Intervention groups
-
treatment group: 2% dorzolamide eye drops (Dorzamid, Sinadaroo, Tehran, Iran) will be administered since one day prior to surgery and continued for 4 weeks postoperatively, every 8 hours.
control group: artificial tears (Tearlose, Sinadaroo, Tehran, Iran) will be given at the same dosage as the treatment group. Additionally, all patients will receive 0.1% betamethasone eye drops every 3 hours during the first week post-surgery, tapered to once daily by the fourth week. Furthermore, 0.3% ciprofloxacin eye drops will be administered every 6 hours for all patients during the first week following the surgery.
-
Main outcome variables
-
Central macular thickness (CMT)